---
document_datetime: 2024-09-05 09:25:40
document_pages: 13
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/betmiga-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: betmiga-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 7.7509501
conversion_datetime: 2025-12-20 01:55:10.630094
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Betmiga

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------|
| X/0039/G             | This was an application for a group of variations. Extension application to introduce a new pharmaceutical form associated with new strength (8 mg/ml prolonged-release granules for oral suspension), grouped with a type II variation | 27/06/2024                          | 22/08/2024                                  | SmPC, Labelling and PL           | Please refer to Scientific Discussion 'Betmiga EMEA/H/C/002388/X/0039/G\". |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 to less than 18 years. The RMP (version 9.2) is updated in accordance. Furthermore, the PI is brought in line with the latest QRD template version 10.4. Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |                 | (C.I.6.a) to include   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------|
| IAIN/0048 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                          | 16/04/2024 | 22/08/2024 | Annex II and PL |                        |
| IA/0047   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                          | 03/11/2023 | n/a        |                 |                        |
| IB/0046   | B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS                                                                                                                                                                                                                                                                                                                      | 13/06/2023 | n/a        |                 |                        |
| IA/0045/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name                                                                                                                                                                                                                                                                                                                                                                                                 | 01/02/2023 | n/a        |                 |                        |

<div style=\"page-break-after: always\"></div>

|           | and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                    |            |     |           |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| IB/0044/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other | 23/11/2022 | n/a | variation |
| IB/0041   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                         | 09/08/2022 | n/a |           |
| IA/0043   | B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material                                                                                                                                                                                                                                                                                                                   | 08/07/2022 | n/a |           |

<div style=\"page-break-after: always\"></div>

| IB/0040             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                               | 06/07/2022   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0042             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                         | 04/07/2022   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| PSUSA/10031 /202106 | Periodic Safety Update EU Single assessment - mirabegron                                                                                                                                                                                                             | 10/02/2022   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0038             | B.II.e.1.b.3 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Deletion of an immediate packaging container without a complete deletion of a strength or pharmaceutical form                                    | 26/10/2021   | 21/09/2022 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0036             | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                           | 05/10/2021   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0033             | Final study report of the PASS Study 178-CL-114 - An evaluation of Cardiovascular Events in Users of Mirabegron and Other Treatments for Overactive Bladder. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission | 29/10/2020   | n/a        |                        | The MAH submitted with this variation the final results of the Post-Authorisation Safety Study 178-CL-114. This study was conducted to investigate the cardiovascular events of mirabegron (especially in elderly). The results of the study did not find higher risk of MACE, AMI, stroke, CV mortality or all-cause mortality among current users of mirabegron as compared to current users of antimuscarinic |

<div style=\"page-break-after: always\"></div>

|           | of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |    | medications, and the Committee agreed there was no need to update the product information. RMP, version 8.0 was updated to reflect the completion of the study and to bring it in line with GVP rev.2 template.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0034    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 30/03/2020 | 21/09/2022 | PL |                                                                                                                                                                                                                   |
| IB/0035/G | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size | 25/03/2020 | n/a        |    |                                                                                                                                                                                                                   |
| IA/0032/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 27/09/2019 | n/a        |    |                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                     | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)   |            |            |             |                                                                                                                                            |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| II/0030             | Submission of the final report of the Drug Utilization Study of mirabegron using real-word healthcare databases from the NL, ES, UK and FI (study 178- PV-002), as agreed via MEA 009.2. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                        | 14/06/2019 | n/a        |             |                                                                                                                                            |
| PSUSA/10031 /201806 | Periodic Safety Update EU Single assessment - mirabegron                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 31/01/2019 | 02/04/2019 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10031/201806. |
| IB/0029             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 20/06/2018 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| PSUSA/10031 /201706   | Periodic Safety Update EU Single assessment - mirabegron                                                                                                                                                                                                                                                                             | 11/01/2018   | n/a        |                        | PRAC Recommendation - maintenance   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------|
| IA/0028               | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                                                         | 12/10/2017   | n/a        |                        |                                     |
| R/0026                | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                              | 20/07/2017   | 18/09/2017 | SmPC, Labelling and PL |                                     |
| PSUSA/10031 /201606   | Periodic Safety Update EU Single assessment - mirabegron                                                                                                                                                                                                                                                                             | 12/01/2017   | n/a        |                        | PRAC Recommendation - maintenance   |
| IB/0025/G             | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size | 14/12/2016   | n/a        |                        |                                     |
| IA/0023               | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                     | 14/09/2016   | n/a        |                        |                                     |
| IA/0022               | B.II.e.6.b - Change in any part of the (primary)                                                                                                                                                                                                                                                                                     | 28/07/2016   | n/a        |                        |                                     |

<div style=\"page-break-after: always\"></div>

|                     | packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10031 /201512 | Periodic Safety Update EU Single assessment - mirabegron                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 07/07/2016 | n/a | PRAC Recommendation - maintenance |
| IA/0021             | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 25/05/2016 | n/a |                                   |
| IA/0020/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place | 04/05/2016 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/10031 /201506   | Periodic Safety Update EU Single assessment - mirabegron                                                                                                                                                                                  | 28/01/2016   | 31/03/2016   | SmPC, Annex II and PL   | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10031/201506.                                                                                                                                               |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0018               | B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products | 22/03/2016   | n/a          |                         |                                                                                                                                                                                                                                                                                          |
| PSUSA/10031 /201412   | Periodic Safety Update EU Single assessment - mirabegron                                                                                                                                                                                  | 23/07/2015   | 14/09/2015   | SmPC and PL             | Please refer to Betmiga EMEA/H/C/PSUSA/00010031/201412 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation                                                                                                                   |
| PSUV/0015             | Periodic Safety Update                                                                                                                                                                                                                    | 22/01/2015   | 16/03/2015   | SmPC and PL             | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0015.                                                                                                                                                        |
| PSUV/0013             | Periodic Safety Update                                                                                                                                                                                                                    | 25/09/2014   | 19/11/2014   | SmPC and PL             | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0013.                                                                                                                                                        |
| IAIN/0014             | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                            | 24/06/2014   | n/a          |                         |                                                                                                                                                                                                                                                                                          |
| PSUV/0007             | Periodic Safety Update                                                                                                                                                                                                                    | 20/02/2014   | 23/04/2014   | SmPC, Annex II and PL   | Please refer to Betmiga-2388-PSUV-0033 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation. In addition the MAH took the opportunity to update the list of local representatives in the package leaflet. Furthermore, the PI |

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                        | is being brought in line with the latest QRD template version 9.   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------|
| IAIN/0012   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 10/03/2014 | n/a        |                        |                                                                    |
| IAIN/0010/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 05/02/2014 | 20/02/2014 | SmPC, Labelling and PL |                                                                    |
| N/0011      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 27/01/2014 |            | PL                     |                                                                    |
| IB/0009     | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 09/12/2013 | n/a        |                        |                                                                    |

<div style=\"page-break-after: always\"></div>

|             | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |     |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0008/G   | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall | 06/12/2013 | n/a |
| IAIN/0006/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV and/or QPPV contact details and/or back-up procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 16/09/2013 | n/a |

<div style=\"page-break-after: always\"></div>

|             | - Changes to an existing pharmacovigilance as described in the DDPS - Other change(s) the DDPS that does not impact on the operation of PhV system                                                                                                                                                                                                                                                                                                                                     |            |     | C.I.9.c system to the   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------|
| IAIN/0005/G | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where takes place | 13/09/2013 | n/a | batch control/testing   |
| IAIN/0004/G | This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of system    | 14/05/2013 | n/a | the pharmacovigilance   |

<div style=\"page-break-after: always\"></div>

| IAIN/0003   | C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV                                                                                                                                                                                                                                         | 17/04/2013   | n/a        |                                  |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|
| IAIN/0002/G | This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system | 20/02/2013   | n/a        |                                  |
| IAIN/0001/G | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release                                                                                                                          | 19/02/2013   | 20/02/2014 | SmPC, Annex II, Labelling and PL |